Morning Market Losers
Model N (NYSE: MODN) dropped 31.57% to $10.08 on downbeat FY14 forecast. JP Morgan downgraded the stock from “overweight” to “neutral.”
Neurocrine Biosciences (NASDAQ: NBIX) plummeted 29.82% to $11.72 after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia.
ChemoCentryx (NASDAQ: CCXI) dropped 23.97% to $6.28 after the company announced top-line interim results for CCX140 in an ongoing Phase II trial.
HD Supply Holdings (NASDAQ: HDS) dropped 11.59% to $21.88 on Q2 results.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.